PMID- 36355214
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20221205
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 30
IP  - 12
DP  - 2022 Dec
TI  - Clinicians' experience with topical benzydamine and morphine for the management 
      of oral mucositis: adverse effects and barriers.
PG  - 10255-10262
LID - 10.1007/s00520-022-07443-2 [doi]
AB  - INTRODUCTION: Among the evidence-based agents outlined in the Multinational 
      Association of Supportive Care in Cancer/International Society of Oral Oncology 
      (MASCC/ISOO) mucositis guidelines, benzydamine and morphine are advised for the 
      management of oral mucositis (OM) in certain cancer patients. This study is aimed 
      to collect information from a group of highly experienced healthcare 
      professionals in the field of oral mucositis about their clinical experience with 
      these agents. METHODS: A survey questionnaire about the clinical experience with 
      topical benzydamine and morphine to manage oral mucositis and their related 
      adverse effects (AEs) was electronically distributed to the members of the 
      Mucositis Study Group of MASCC/ISOO. RESULTS: Eighty-eight entries were recorded 
      (response rate 25%), and 54 entries submitted complete questionnaires about the 
      drug-related AE (completion rate 65%) and were used for the data analysis. Of the 
      respondents, 44% and 27.7% prescribed benzydamine and morphine to manage their 
      patients' oral mucositis, respectively. Lack of availability in the respondent's 
      country was the common reason for not prescribing benzydamine and morphine (18.9% 
      and 5.4%, respectively); however, a large portion of the respondents indicated 
      that 'another reason' stopped them from prescribing these agents (51.3% and 73%, 
      respectively). AEs to benzydamine or morphine were observed by 25.9% and 12.9% of 
      respondents, respectively, with mild numbness and tingling as the most common 
      drug-related AE for both agents. CONCLUSION: The use of topical benzydamine and 
      morphine for the management of OM varies between countries. While relatively 
      common, the AEs related to these agents are mild. Mitigating the barriers for 
      prescribing them may increase their use.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Blanchard, Ariel
AU  - Blanchard A
AD  - Division of Oral & Maxillofacial Surgery, Department of Surgery, New York 
      Presbyterian Hospital - Weill Cornell Medical Center, New York, NY, USA. 
      aab9028@med.cornell.edu.
FAU - Yarom, Noam
AU  - Yarom N
AD  - Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel.
AD  - School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Levi, Lauren
AU  - Levi L
AD  - Department of Oral & Maxillofacial Surgery, Division of Orofacial Pain, Thomas 
      Jefferson Hospital, Philadelphia, PA, USA.
FAU - Cheng, Karis Kin Fong
AU  - Cheng KKF
AD  - Global Nursing Research Center, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Bossi, Paolo
AU  - Bossi P
AD  - Department of Medical and Surgical Specialties, Radiological Sciences and Public 
      Health - Medical Oncology, ASST-Spedali Civili, University of Brescia, Brescia, 
      Italy.
FAU - Zadik, Yehuda
AU  - Zadik Y
AD  - Department of Military Medicine, Faculty of Medicine, Hebrew University of 
      Jerusalem, Jerusalem, Israel.
AD  - Department of Oral Medicine, Faculty of Dental Medicine, Hebrew University of 
      Jerusalem, Jerusalem, Israel.
FAU - Elad, Sharon
AU  - Elad S
AD  - Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical 
      Center, Rochester, NY, USA.
CN  - Atask force of the Mucositis Study Group of the Multinational Association of 
      Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
LA  - eng
PT  - Journal Article
DEP - 20221110
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 4O21U048EF (Benzydamine)
RN  - 76I7G6D29C (Morphine)
SB  - IM
MH  - Humans
MH  - *Benzydamine/adverse effects
MH  - *Mucositis
MH  - Morphine/adverse effects
MH  - *Stomatitis/chemically induced/drug therapy
MH  - *Neoplasms
MH  - *Drug-Related Side Effects and Adverse Reactions
OTO - NOTNLM
OT  - Benzydamine
OT  - Management
OT  - Morphine
OT  - Mucositis
OT  - Oral
OT  - Pain
OT  - Topical
EDAT- 2022/11/11 06:00
MHDA- 2022/12/06 06:00
CRDT- 2022/11/10 11:16
PHST- 2022/04/23 00:00 [received]
PHST- 2022/10/30 00:00 [accepted]
PHST- 2022/11/11 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/11/10 11:16 [entrez]
AID - 10.1007/s00520-022-07443-2 [pii]
AID - 10.1007/s00520-022-07443-2 [doi]
PST - ppublish
SO  - Support Care Cancer. 2022 Dec;30(12):10255-10262. doi: 
      10.1007/s00520-022-07443-2. Epub 2022 Nov 10.